Below are new therapies for cancer care :
Non-Small Cell Lung Cancer -
1) First Line Pembrolizumab Improves Survival vs Platinum-Based Chemotherapy in Advanced PD-L1-Positive NSCLC
Pembrolizumab significantly improved progression-free and overall survival vs platinum-based chemotherapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC) with >= 50% PD-L1 (programmed cell death ligand 1) expression and no sensitizing EGFR mutations or ALK translocations. Reck et al reported these findings from the phase III KEYNOTE-024 trial in The New England Journal of Medicine.
2) FDA Approves Atezolizumab for Advanced Non-Small Cell Lung Cancer